Can CAR T-cell therapy cure CLL? An update

Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL who have received chimeric antigen receptor T-cell therapy against CD19 (CART-19) are now available.